1. Signaling Pathways
  2. Vitamin D Related/Nuclear Receptor
  3. Estrogen Receptor/ERR

Estrogen Receptor/ERR

Estrogen receptors are a group of proteins found inside cells. They are receptors that are activated by the hormone estrogen (17β-estradiol). Two classes of estrogen receptor exist: ER, which is a member of the nuclear hormone family of intracellular receptors, and GPER (GPR30), which is a member of the rhodopsin-like family of G protein-coupled receptors. The ER's helix 12 domain plays a crucial role in determining interactions with coactivators and corepressors and, therefore, the respective agonist or antagonist effect of the ligand. Different ligands may differ in their affinity for alpha and beta isoforms of the estrogen receptor: estradiol binds equally well to both receptors, estrone, and raloxifene bind preferentially to the alpha receptor, estriol, and genistein to the beta receptor. Estrogen and its receptors are essential for sexual development and reproductive function, but also play a role in other tissues such as bone. Estrogen receptors are also involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. Alternative promoter usage and alternative splicing result in dozens of transcript variants, but the full-length nature of many of these variants has not been determined.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0709
    Estradiol acetate
    Estradiol acetate is a novel orally active Estradiol (HY-B0141) prodrug. Estradiol acetate reduces the frequency and severity of postmenopause symptoms. Estradiol acetate can be used in the research of menopausal symptoms.
    Estradiol acetate
  • HY-120207
    (R)-GDC-0927
    Antagonist 98.78%
    (R)-GDC-0927 ((R)-SRN-927) is a (R)-enantiomer of GDC-0927 (HY-111484).
    (R)-GDC-0927
  • HY-W727814
    Pipendoxifene-d10
    Pipendoxifene-d10 (ERA-923-d10) is the deuterium labeled Pipendoxifene (HY-13724). Pipendoxifene is a selective estrogen receptor modulator (SERM).
    Pipendoxifene-d<sub>10</sub>
  • HY-179002
    (S)-STO021
    Agonist
    (S)-STO021 is a highly selective, orally effective ERβ agonist. (S)-STO021 has a dual activity of inhibiting osteoclast activity and promoting osteoblast activity. (S)-STO021 can be used for research on osteoporosis.
    (S)-STO021
  • HY-A0287
    Clomiphene
    Clomiphene (Clomifene; (Z/E)-Enclomiphene; (Z/E)-Enclomifene) is an orally active ovulation-inducing agent. Clomiphene binds to hypothalamic estrogen receptors to elevate FSH levels, and exhibits antiestrogenic or estrogenic properties. Clomiphene can induce erturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes. Clomiphene ameliorates memory impairment in PCOS models. Clomiphene mobilizes cytosolic calcium and reduces viability in prostate cancer cells. Clomiphene can be used for the research of polycystic ovary syndrome (PCOS) and prostate cancer.
    Clomiphene
  • HY-172869
    Estrogen receptor antagonist 9
    Antagonist
    Estrogen receptor antagonist 9 (Compound 5D) is an estrogen receptor antagonist. Estrogen receptor antagonist 9 shows significant cytotoxicity against MCF7 cells with an IC50 value of 8.50 μM. Estrogen receptor antagonist 9 is promising for research of breast cancers.
    Estrogen receptor antagonist 9
  • HY-N11787
    Cimicifuga racemosa extract
    Inhibitor
    Cimicifuga racemosa extract is a herbal remedy with antiestrogenic properties found in the plant Cimicifuga racemosa, commonly used to alleviate menopausal symptoms and relieve symptoms such as hot flashes and night sweats.
    Cimicifuga racemosa extract
  • HY-144137
    Estrogen receptor antagonist 1
    Antagonist
    Estrogen receptor antagonist 1 is a selective estrogen receptor antagonist. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 1 has the potential for the research of breast cancer diseases (extracted from patent WO2021249533A1, compound 4).
    Estrogen receptor antagonist 1
  • HY-168101
    ERα degrader 11
    Degrader
    ERα degrader 11 (compound B16) is a selective ERα degrader that can be used as an estrogen receptor probe to investigate ER status in ER-positive breast cancer cells.
    ERα degrader 11
  • HY-176388
    ER ligand-12
    ER ligand-12 is an estrogen receptor (ER) ligand that can be used in the synthesis of PROTACs, such as PROTAC ER Degrader-2 (HY-128528).
    ER ligand-12
  • HY-129099AR
    N-Desmethyltamoxifen hydrochloride (Standard)
    Antagonist
    N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
    N-Desmethyltamoxifen hydrochloride (Standard)
  • HY-170806
    ERα degrader 12
    Degrader
    ERα degrader 12 (Compound RA3) is an estrogen receptor α (ERα) degrader with antitumor properties. ERα degrader 12 induces pronounced tumor growth inhibition in a breast cancer xenograft mouse model.
    ERα degrader 12
  • HY-125675
    VPC-16606
    Inhibitor
    VPC-16606 is a selective inhibitor targeting the activation function 2 (AF2) domain of estrogen receptor α (ERα). VPC-16606 blocks the interaction between ERα and coactivators, inhibits the activity of both wild-type and clinically drug-resistant mutant ERα, and exerts inhibitory effects on hormone-resistant breast cancer cells. VPC-16606 can be used in breast cancer research.
    VPC-16606
  • HY-178463
    F0840-0093
    Degrader
    F0840-0093 is a highly selective estrogen receptor α (ERα) degrader. F0840-0093 exhibits potent antiproliferative activity against T47D cells with an IC50 value of 4.65 μM. F0840-0093 is promising for research of estrogen receptor-positive (ER+) breast cancer.
    F0840-0093
  • HY-172067
    ER ligand-9
    ER ligand-9 is a conjugate of an estrogen receptor (Estrogen Receptor/ERR) and a linker, which can be used to synthesize PROTAC ERD-1233 (HY-169367).
    ER ligand-9
  • HY-W654296
    Octocrylene-13C3
    Octocrylene-13C3 is the 13C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes.
    Octocrylene-<sup>13</sup>C<sub>3</sub>
  • HY-123163
    JNJ-1250132
    Inhibitor
    JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC50 of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC50=0.50 nM) and the rat androgen receptor (AR) (IC50=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC50 >3000 nM).
    JNJ-1250132
  • HY-118786
    Tamoxifen analog II
    Tamoxifen analog II, a cyclopropyl derivative of Stilbene, is a nonsteroidal antiestrogen. Tamoxifen analog II has antiestrogenic activity. Tamoxifen analog II inhibits the growth of DMBA (HY-W011845)-induced rat mammary tumors.
    Tamoxifen analog II
  • HY-18719BR
    Endoxifen hydrochloride (Standard)
    Inhibitor
    Endoxifen (hydrochloride) (Standard) is the analytical standard of Endoxifen (hydrochloride). This product is intended for research and analytical applications. Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study[1][2].
    Endoxifen hydrochloride (Standard)
  • HY-164924
    ERD-12310A
    Degrader
    ERD-12310A is a PROTAC targeting Estrogen Receptor α (ERα) with a ED50 value of 47 pM. ERD-12310A has oral activity. ERD-12310A is composed of PROTAC target protein ligand ER ligand-4 (HY-164925) (red part), E3 ligase ligand (S)-Deoxy-thalidomide (HY-168055) (blue part). ERD-12310A can be used in the research of ER+ breast cancer.
    ERD-12310A
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.